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Summary
Tumors of the same histologic type often comprise clinically and molecularly distinct subgroups; however, the etiology of
these subgroups is unknown. Here, we report that histologically identical, but genetically distinct, ependymomas exhibit
patterns of gene expression that recapitulate those of radial glia cells in the corresponding region of the central nervous
system. Cancer stem cells isolated from ependymomas displayed a radial glia phenotype and formed tumors when ortho-
topically transplanted in mice. These findings identify restricted populations of radial glia cells as candidate stem cells of
the different subgroups of ependymoma, and they support a general hypothesis that subgroups of the same histologic
tumor type are generated by different populations of progenitor cells in the tissues of origin.S I G N I F I C A N C E
The failure of tumor histology to accurately predict the clinical behavior of human cancer presents a fundamental hurdle to the
development of effective treatments for malignant disease. We present evidence that histologically identical subsets of ependy-
moma arise from distinct populations of progenitor cells in the nervous system. Our data suggest a mechanism to explain clinical
heterogeneity among microscopically similar cancers. Cancer treatments should be targeted to the cell signal pathways that
maintain subsets of cancer stem cells rather than the histological or clinical forms of the disease.Introduction
Historically, the diagnosis and treatment of cancer have been
based primarily on tumor histology. However, this approach
has proven inadequate, as morphologically similar cancers
often display variable clinical behavior. Recently, genome-wide
expression profiling has unmasked molecularly distinct sub-
groups among tumors of the same histological type (Nutt et
al., 2003; Sotiriou et al., 2003; Yeoh et al., 2002). While these
data provide insights into the complexities of human cancer,
the etiology of the cancer subgroups remains to be deter-
mined.
Recent evidence suggests that cancers arise as the conse-
quence of aberrant development in which the bulk of the malig-
nant cells are maintained by a rare fraction of transformed stem
cells, termed cancer stem cells (Pardal et al., 2003; Warner et
al., 2004). Cancer stem cells are phenotypically similar to the
normal stem cells of the corresponding tissue of origin, but
they exhibit dysfunctional patterns of self-renewal and differen-CANCER CELL : OCTOBER 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIERtiation (Bonnet and Dick, 1997; Hemmati et al., 2003; Ignatova
et al., 2002; Lapidot et al., 1994; Singh et al., 2004b). For exam-
ple, astrocytic and embryonal brain tumors contain rare popula-
tions of cancer stem cells that are capable of self-renewal in vitro
and of propagating the original tumor in vivo (Hemmati et al.,
2003; Ignatova et al., 2002; Singh et al., 2003, 2004b; Yuan et
al., 2004). These stem cell-like properties are restricted to brain
tumor cells that express the neural stem cell marker CD133
(Uchida et al., 2000).
If cancers arise from transformed stem cells, then subgroups
of the same histologic tumor type might be derived from distinct
populations of progenitor cells in the tissue of origin. Indeed,
recent studies indicate that clinically and molecularly distinct
subgroups of acute lymphoblastic leukemia originate at dif-
ferent stages of the hematopoietic lineage (Castor et al., 2005).
Comparative studies of normal and malignant hematologic
stem cells have been facilitated by the availability of robust as-
says for all stages of hematopoiesis (Warner et al., 2004). In con-
trast, knowledge of the stem and progenitor cell populationsINC. DOI 10.1016/j.ccr.2005.09.001 323
A R T I C L E324 CANCER CELL : OCTOBER 2005
A R T I C L Eof nonhematologic organs is limited; therefore, determining
whether different progenitors might generate subtypes of histo-
logically similar solid tumors is less straightforward. Neverthe-
less, the central nervous system (CNS) represents an attractive
system in which to study this hypothesis, since it comprises a
set of anatomically and developmentally distinct tissue com-
partments that are each affected by a common set of tumors.
Ependymomas are CNS tumors that originate from the wall
of the ventricular system along the entire craniospinal axis
(Kleihues et al., 2002). Although ependymomas from different
regions of the CNS are histologically indistinguishable, they
display distinct patterns of clinical behavior (Bouffet et al.,
1998) and chromosomal abnormalities (Dyer et al., 2002; Ebert
et al., 1999), suggesting that they represent a collection of dif-
ferent diseases. We hypothesized that ependymomas from the
supratentorial region, the posterior fossa (fourth ventricle), and
the spinal cord are clinically heterogeneous because they arise
from different populations of neural progenitor cells. We show
that the gene expression profiles of human supratentorial and
spinal ependymomas are shared by murine embryonic radial
glia cells (RGCs) in the subventricular zone of the lateral ventri-
cles and spinal canal, respectively. Further, we demonstrate
that ependymomas contain a rare population of RGC-like can-
cer stem cells that are both required and sufficient to propa-
gate the disease as orthotopic transplants in mice. In addition,
we found that ependymomas arising from different parts of the
CNS contain distinct chromosomal abnormalities that also
contribute to the gene expression signatures of these tumors.
Thus, our data identify restricted populations of RGCs as can-
didate cells of origin of the different anatomic subgroups of
ependymomas. Furthermore, the experimental approach that
we have used could be employed to identify cellular targets of
primary mutations and malignant transformation in other solid
tumors.
Results
Ependymomas from different parts of the CNS
are molecularly distinct diseases
We used a combination of oligonucleotide gene expression ar-
rays and array comparative genomic hybridization (aCGH) to
determine the degree to which ependymomas from different
regions of the CNS are molecularly distinct diseases. We ana-
lyzed a total of 103 ependymomas, including 32 fresh-frozen
tumors and a nonoverlapping set of 71 formalin-fixed tumors
that were incorporated into a tissue microarray (TMA). We
found that subsets of ependymoma exhibited distinct patterns
of gene expression (Figure 1A) and regions of chromosomeFigure 1. Ependymomas from different parts of the CNS are molecularly distinct diseases
Unsupervised hierarchical cluster analyses of gene expression profiles of 29 ependymomas (histologic variants are classic [“C”] and anaplastic [“A”]) (A)
and aCGH data sets of the same 29 tumor samples plus one additional supratentorial and two posterior fossa tumors (B). Tumor color codes are the same
as in A. Reference numbers of the bacterial artificial chromosome (BAC) clones that reported significantly altered chromosome (Chr) regions are shown
to the right. In B, black boxes denoted “F” identify BAC clones that were employed for fluorescence in situ hybridization (FISH) analysis of our TMA, the
results of which are shown in C. Three separate subgroups (1–3) of posterior fossa tumors are identified by aCGH. Group 1 has a balanced karyotype,
group 2 has a collection of amplifications on various autosomes, and group 3 shows amplification of chromosome 1q. C: Confirmation of aCGH data by
FISH analysis of our ependymoma TMA. Heterozygous or homozygous deletions of p16 were detected in four of six supratentorial tumors but in only 1 of 69
other informative ependymomas (Fisher’s test, p < 0.0001). Multiple, concurrent, nonrandom DNA amplifications were detected in eight posterior fossa
tumors (group 2), which were distinct from tumors that demonstrated gain of 1q (group 3).
Ramain et al., 1996) or Hox-c (Suemori and Noguchi, 2000),CANCER CELL : OCTOBER 2005gain and loss (Figure 1B) that correlated with the anatomic lo-
cation of the tumor (supratentorial region, posterior fossa, or
spine), but not with clinical parameters (patient age or sex) or
with tumor histologic grade (classic or anaplastic). Fluores-
cence in situ hybridization (FISH) analysis of our ependymoma
TMA validated the results of our aCGH experiment (Figures 1B
and 1C). In this regard, we confirmed that P16 INK4A (located at
9p21.3) is selectively deleted in >90% of tumor cell nuclei of
supratentorial ependymomas but is rarely deleted in tumors
arising in other regions of the CNS (p < 0.0001). Three sub-
groups of posterior fossa ependymoma that were identified by
aCGH were also confirmed using FISH analysis (Figures 1B
and 1C). These included a set of tumors that contained multi-
ple concurrent DNA amplifications, and a further set of tumors
that gained chromosome 1q (Figure 1C). In agreement with the
results of chromosome CGH studies, around one-half of poste-
rior fossa ependymomas exhibited a balanced karyotype (Dyer
et al., 2002). Deletions of chromosome 22q12 that we detected
in two spinal ependymomas and one posterior fossa ependy-
moma are a well-described feature of this disease (Ebert et al.,
1999; Huang et al., 2002; Suarez-Merino et al., 2005). Thus,
morphologically similar ependymomas that arise within dif-
ferent regions of the CNS are molecularly distinct diseases.
Ependymomas recapitulate the gene expression
profiles of regionally specified RGCs
The gene expression signatures that distinguished supratentor-
ial, posterior fossa, and spinal ependymomas include genes
that regulate neural precursor cell proliferation and differentia-
tion in the corresponding region of the CNS (Figure 2A; see
Table S1 in the Supplemental Data available with this article
online for a full list of genes). For example, supratentorial tu-
mors express markedly elevated levels of members of the
EPHB-EPHRIN and NOTCH cell signal systems that play key
roles in maintaining normal neural stem cells in the cerebral
SVZ (Conover et al., 2000; Hitoshi et al., 2002) (Figure 2A). In-
terference with normal EphB-Ephrin interactions in SVZ cells
of mice disrupts neuroblast chain migration and dramatically
increases astrocyte proliferation, resulting in the formation of
hyperplastic polyps along the ventricle surface (Conover et al.,
2000). Conversely, spinal ependymomas expressed multiple
Homeobox (HOX) family members (Figure 2A). HOX genes en-
code transcription factors that coordinate anteroposterior tis-
sue patterning during development (Dasen et al., 2003; Kmita
and Duboule, 2003). In vertebrates, successively more caudal
body regions show an increase in the amount and diversity
of HOX expression, and deletion of either Hoxa9 (Fromental-325
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mas (Figure 2A), causes spinal abnormalities in mice. We con-
firmed these gene expression patterns by performing immuno-
histochemical analyses of our ependymoma TMA (Figures 2B
and 2C). Importantly, because FISH analysis showed that the
great majority of ependymoma cells within our TMA are cancer
cells (Figure 1C), these immunohistochemical data also confirm
that ependymoma gene expression patterns are generated by
cancer cells and not by entrapped normal cells.
Previously, molecular signatures of cancers derived from
gene expression microarray studies have been linked to the
presence of specific mutations in tumor subtypes (Aguirre et
al., 2004); however, our data suggest a different interpretation.
Alternatively, it is possible that subsets of ependymoma either
maintain or recapitulate the developmental expression profiles
of anatomically restricted progenitor cells. Thus, mapping the
site of expression of these genes might pinpoint the normal cell
populations from which ependymomas arise. Therefore, using in
situ hybridization, we mapped the expression in embryonic
mouse CNS of 77 genes that clearly distinguished supratentor-
ial, posterior fossa, and spinal ependymomas (see Table S2
for a full list of genes). Almost all signature genes of human
supratentorial ependymomas were expressed in the wall of the
cerebral ventricles at embryonic day 11 (E11), and in the ventral
SVZ of the lateral ventricles at E15 (Figures 3A and 3D). How-
ever, these genes were rarely expressed in the wall of the fourth
ventricle or in the spinal cord. Conversely, all of the signature
genes of spinal ependymoma were expressed in the wall of
the developing spinal canal and the ventrolateral spinal cord,
whereas less than one-third was present in the brain (Figures
3C and 3D). The gene expression signatures of supratentorial
and spinal ependymomas correlated significantly with those of
the corresponding region of the normal developing CNS at E11
and E15 (Figure 3D; p < 0.05). Although cells lining the fourth
ventricle contained transcripts of proportionately more signa-
ture genes of human posterior fossa ependymoma, these
genes were also expressed in the wall of the lateral ventricles
and the spinal canal (Figures 3B and 3D).
Interestingly, the intense expression of supratentorial epen-
dymoma signature genes that we observed in the ventral wall
of the lateral ventricle between E11 and E15 coincides pre-
cisely with the time that normal ependymal cells arise from
RGCs in this region of the brain (Spassky et al., 2005). RGCs
constitute a heterogeneous population of multipotent neural
precursor cells that display significant differences in gene ex-
pression and function among CNS regions (Hartfuss et al.,
2001; Kriegstein and Gotz, 2003; McMahon and McDermott,
2002; Russo et al., 2004). Therefore, we reasoned that RGCs
might represent the site of expression of ependymoma signa-
ture genes in the supratentorial SVZ and spinal canal and thatFigure 2. Regulators of neural stem cell proliferation and differentiation are signature genes of ependymomas from different parts of the CNS
A: Supervised hierarchical cluster analysis of oligonucleotide gene expression profiles of supratentorial (ST), posterior fossa (PF), and spinal (SP) ependymo-
mas. “Fold” and “p value” denote the magnitude and significance of the difference in gene expression among anatomic tumor subgroups.
B: Examples of immunohistochemical analyses of ten supratentorial, 40 posterior fossa, and 21 spinal ependymomas confirming the differential expression
between anatomic tumor subgroups of genes detected by gene expression profiling.
C: Differences in the expression of these proteins were quantified by counting the numbers of immunoreactive tumor cells in each tumor. Pink, blue, and
yellow bars denote supratentorial, posterior fossa, and spinal tumors, respectively. Each bar reports average (±SE) number of immunoreactive tumor cells.
Differences in the expression of proteins among tumor subgroups were determined by the Kruskall-Wallis test; *p < 0.05; **p < 0.005; ***p < 0.0005.
SVZ. Neuroepithelial cells represent the earliest progenitors inCANCER CELL : OCTOBER 2005they could be cells of origin of these ependymoma subtypes.
To test this hypothesis, we used coimmunofluorescence to col-
ocalize RGC-specific antigens and ependymoma signature
genes in the ventral wall of the lateral ventricle and the spinal
canal (Figure 3E). These studies confirmed that signature
genes of ependymomas are indeed expressed by RGCs in the
corresponding region of the CNS and suggest the hypothesis
that the distinct populations of RGCs that exist within the brain
and spine (Hartfuss et al., 2001; Kriegstein and Gotz, 2003) are
the cells of origin of supratentorial and spinal ependymomas,
respectively.
Ependymomas contain rare populations of RGC-like cells
that self-renew and are multipotent in culture
Normal and malignant neural stem cells may be isolated in cul-
ture as clonally derived colonies termed neurospheres (Reyn-
olds and Weiss, 1992). Neurosphere (hereon termed tumor
sphere)-forming cells isolated from medulloblastoma and gli-
oma express the neural stem cell marker CD133 and exhibit
the ability to self-renew and differentiate along divergent neu-
ronal lines (Hemmati et al., 2003; Ignatova et al., 2002; Singh
et al., 2003; Uchida et al., 2000; Yuan et al., 2004). We rea-
soned that if RGCs are stem cells of ependymoma, then cancer
stem cells of this tumor should be capable of self-renewal, be
multipotent, and express markers of RGCs.
To test this hypothesis, we generated single-cell suspen-
sions from samples of freshly resected intracranial (n = 4) and
spinal pediatric ependymoma (n = 1) and cultured these under
conditions that favor stem cell growth. We also confirmed that
each of these cell populations comprised tumor cells and not
normal brain cells, by performing spectral karyotyping (Table
S3). All five ependymomas were found to contain a minority
cell population that generated clonally derived tumor spheres
at a frequency ranging from 0.34% to 0.74% (Table S3). This
frequency of primary tumor sphere-forming cells is very similar
to that reported for pilocytic astrocytoma; another relatively
slow-growing pediatric brain tumor (Singh et al., 2003).
To assay the self-renewal capacity of ependymoma tumor
sphere-forming cells, we dissociated primary tumor spheres
and replated single-cell suspensions of these cells at serial di-
lutions down to one cell per well. Primary tumor sphere-derived
cells formed secondary spheres with a range of 0.53 to 1.0
secondary sphere/100 primary sphere cells (mean 0.75 ± 0.22
SE) over a period of 1–2 weeks. Thus, ependymomas contain
a rare fraction of cells that self-renew under stem cell culture
conditions.
To determine if tumor sphere-forming ependymoma cells might
be derived from RGCs, we looked in these cells for marker pro-
teins characteristic of different stages of differentiation in the327
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A–C: In situ hybridization analysis showing expression in E11 whole embryo and E15 mouse brain and spinal cord of signature genes of human supratentorial
(A), posterior fossa (B), and spinal (C) ependymoma. Arrows in B identify the IV ventricle.
D: Contour map showing the frequency and site of expression in E15 mouse brain and spine of all 77 genes that clearly distinguished human supratentorial
(STep), posterior fossa (PFep), and spinal (SPep) ependymomas. Color scale reports the percentage of tumor signature genes expressed (see Table S2 for
a full list of genes).
E: Dual immunofluorescence analysis of Jagged1 or Hoxa9 expression by radial glia cells (detected by staining for Blbp) in the wall of the lateral ventricle
(supratentorial), IV ventricle (post. fossa), and spinal canal (spine) in E15 mouse CNS. Arrow indicates Hoxa9 expression within the nucleus of a Blbp+ RGC.328 CANCER CELL : OCTOBER 2005
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and they express CD133, Nestin, and RC2 (Hartfuss et al.,
2001; Uchida et al., 2000). While RGCs also express these pro-
teins, they are distinguished from neuroepithelial cells by the
presence of glial markers including astrocyte-specific gluta-
mate transporter (GLAST) and brain lipid binding protein
(BLBP) (Hartfuss et al., 2001; Kriegstein and Gotz, 2003). As
neurogenesis begins, RGCs give rise to postmitotic neurons,
astrocytes, and ependymal cells expressing appropriate mark-
ers of differentiation but not CD133 or Nestin (Culican et al.,
1990; Hartfuss et al., 2001; Malatesta et al., 2003; Spassky et
al., 2005; Uchida et al., 2000). We found that all ependymoma-Figure 4. Tumor sphere-forming ependymoma cells display a radial glia cell
immunophenotype
Clonally derived secondary tumor spheres generated by ependymoma
and medulloblastoma stem cell-like cells after 7 days in culture express
the neural progenitor cell markers Nestin and CD133. Only ependymoma
spheres expressed RC2 and the radial glia cell marker BLBP.CANCER CELL : OCTOBER 2005derived tumor spheres displayed a CD133+/Nestin+/RC2+/
BLBP+ immunophenotype similar to that of RGCs (Figure 4).
In contrast, tumor spheres generated from pediatric medul-
loblastoma exhibited a CD133+/Nestin+/RC2−/BLBP− pheno-
type. Significantly, analysis of the 71 ependymomas within our
TMA also identified BLBP-expressing tumor cells at an average
frequency of 0.5% (range 0.001% to 1.5% of total tumor cells).
Thus, stem cell-like cancer cells in ependymoma are phenotyp-
ically different from those of medulloblastoma, and they are
likely to arise within the RGC lineage.
To test whether tumor sphere-forming ependymoma cells
are multipotent, we generated single-cell suspensions from
secondary tumor spheres and cultured these in the absence of
both basic fibroblast growth factor and epidermal growth fac-
tor to induce differentiation. Twenty-four hours following disso-
ciation, approximately 70% and 30% of secondary tumor
sphere-derived cells retained expression of BLBP and RC2, re-
spectively (Figures 5A–5D). However, a significant number of
cells had lost expression of CD133 relative to that observed in
the intact tumor spheres (Figures 4, 5A, and 5B). Remarkably,
about 1% of secondary tumor sphere-derived cells also dis-
played an unusual morphology in culture that was reminiscent
of RGCs in the brain (Figures 5E and 5F). After 72 hr in differen-
tiation medium, secondary tumor sphere-derived cells exhib-
ited a dramatic change in immunophenotype. These changes
included loss of the RGC immunophenotype CD133+/RC2+/
BLBP+ (Figures 5A and 5B; and compare Figure 5C with Figure
5G and Figure 5D with Figure 5H) and increased expression of
markers of neuronal (β-III-tubulin and MAP2), astrocytic (GFAP
and S100), and oligodendrocytic (CNPase and NG2) differenti-
ation (Figures 5I–5N). Importantly, FISH analysis of differenti-
ated ependymoma cells confirmed that these are cancer cells
and not normal cells (Figure 5O). Thus, ependymomas contain
a rare fraction of RGC-like cancer cells that display the stem
cell properties of self-renewal and multipotency.
RGC-like ependymoma cancer stem cells
form tumors in nude mice
Although our cell culture assays suggest that ependymomas
contain RGC-like cancer stem cells, the ability of a cell to reca-
pitulate the original tumor in vivo is a far more rigorous assess-
ment of the cancer stem cell phenotype. Therefore, we used im-
munoglobulin-conjugated magnetic beads to isolate CD133+
cells from whole-cell populations of two fresh samples of epen-
dymoma (Figures 6A and 6B). FISH analysis of sorted ependy-
moma cell populations confirmed that both CD133+ and
CD133− fractions comprise cancer cells, since both of these
fractions displayed gain of 1q (Figures 6C and 6D). In keeping
with our analysis of tumor spheres, acutely sorted CD133+
ependymoma cells coexpressed BLBP and RC2 (Figures 6E
and 6F), whereas neither of these proteins were detected in
CD133+ cells isolated from medulloblastoma (Figure 6G and
data not shown). An average of 0.9% (range 0.3%–3.0%) of all
cells within sorted samples of ependymoma displayed a radial
glia-like CD133+/RC2+/BLBP+ immunophenotype, which is
very similar to the incidence of BLBP+ cells that we observed
within whole-tumor sections. We then performed stereotactic
injections of sorted and nonsorted tumor cell populations into
the superficial cerebral cortex of 7-week-old NOD-SCID mice.
Mice injected with as few as 10,000 CD133+/RC2+/BLBP+
ependymoma cells developed signs of neurological impairment329
A R T I C L EFigure 5. Radial glia cell-like ependymoma cells are multipotent
Single cells isolated from secondary ependymoma tumor spheres were
cultured under conditions that induce differentiation. Graphs (A and B)
report changes in the percentage of CD133, RC2, or BLBP expression de-
termined by immunofluorescence among cells isolated from two different
primary ependymomas. Percentages (±SE) were estimated by counting
>1000 cells after 24 hr and 72 hr in culture. The Wilcoxon statistic was used
to estimate the significance of expression differences; *p < 0.05; ***p <
0.0005. Typical expression patterns of RC2 (C) and BLBP (D) among epen-
dymoma cells cultured in differentiation medium for 24 hr. E and F show
examples of the 1% of secondary tumor sphere-derived cells (estimated
by counting 1000 tumor cells) that displayed a morphology of radial glia
cells up to 24 hr in differentiation medium. After 72 hr in differentiation
medium, secondary tumor sphere-derived cells exhibited a dramatic de-
crease in expression of RC2 (G) and BLBP (H) and a concomitant increase
in markers of oligodendrocytic (I and J), astrocytic (K and L), and neuronal
(M and N) differentiation. O: FISH analysis using probes directed against 1p
(green) and 1q (red) confirmed that differentiated cells display gain of 1q
and are therefore cancer cells.between 4 and 5 months postinjection. Analysis of the brains
from these mice revealed the presence of tumors that ap-
peared to arise within the cerebral SVZ and fill the lateral or III
ventricles, resulting in hydrocephalus (Figure 6H). These xeno-
grafts demonstrated characteristic morphologic features of
ependymoma including the following: moderate cellularity; pre-
dominantly monomorphic nuclear morphology; and occasional
pseudorosettes (Figure 6I). CD133+/RC2+/BLBP+ xenografts
also expressed glial fibrillary acidic protein and BLBP, but they
did not exhibit markers of neuronal differentiation such as β-III-330tubulin (Figures 6J–6L). Significantly, xenografts also recapitu-
lated the appropriate site-specific gene expression signature
of the parent tumor. In this regard, CD133+/RC2+/BLBP+ can-
cer stem cells isolated from a posterior fossa ependymoma
generated a xenograft that reproduced the gene expression
signature of the parent posterior fossa tumor, even when trans-
planted into the supratentorial region (Figures 6M–6T). In con-
trast, mice that were injected with up to 2 × 106 CD133− cells
or 2 × 106 unsorted ependymoma cells (n = 10 mice for each
cell population) did not develop tumors up to 1 year following
injection. Histologic examination of the brains of these mice
did not reveal any evidence of tumor engraftment. Therefore,
ependymomas contain a rare fraction of CD133+/RC2+/BLPB+
cancer stem cells that are required and sufficient to generate
tumors in vivo and that transmit a site-specific radial glia-like
expression signature to the mature tumor. Thus, we propose
that ependymoma cancer stem cells are derived from trans-
formed RGCs.
Anatomic site-specific chromosomal alterations
in ependymomas significantly contribute
to tumor gene expression profiles
Studies of leukemia suggest that early transformation events,
e.g., the t(8;21) translocation, are transmitted from the cancer
stem cell to more mature progeny, ultimately impacting the
gene expression profile of the entire malignant clone (Castor et
al., 2005; Miyamoto et al., 2000; Ross et al., 2004; Yuan et
al., 2001). We reasoned that the gene expression signatures of
ependymomas might be similarly influenced by the unique sets
of chromosomal alterations contained within the different ana-
tomic tumor subgroups (Figure 1B). Further, the genes that are
most affected by these chromosome alterations are likely to
include those responsible for driving transformation of ependy-
moma stem cells in the different regions of the CNS.
As a first step to identifying genes that are disrupted by chro-
mosomal alterations in ependymoma, we used a novel statisti-
cal approach to integrate our aCGH and gene expression array
data sets. We first identified all Affymetrix oligonucleotide
probe sets that map within significantly varying bacterial artifi-
cial chromosome (BAC) aCGH clones and correlated DNA
copy number changes with gene expression using the t-like
statistic. We then employed random permutation analysis to
assess the significance of each statistic for each gene. Impor-
tantly, this analysis demonstrated that only a small minority
(12%; n = 86/704) of transcripts within regions of DNA gain
or loss exhibit significant copy number-driven gene expression
(Figure 7; a full list of these genes is provided in Table S4).
However, this correlation was highly significant, since only
0.1% (n = 47/40,785) of probes within balanced chromosome
regions correlated with the alteration of a distal genomic region
(odds ratio = 122; chi-square p < 0.0001). This approach may
identify the minority of genes in altered genomic regions that
contribute to transformation or progression of ependymoma.
These findings also imply that transcriptional differences
among histologically identical tumors are dictated not only by
the cell of origin, but also by the specific genetic events that
promote clonal expansion. We are currently mining these data
to select genes that display clear copy number-driven geneCANCER CELL : OCTOBER 2005
A R T I C L EFigure 6. CD133+/RC2+/BLBP+ ependymoma
stem cells form tumors in mice
Whole-cell populations of ependymomas were
sorted to isolate CD133+/RC2+/BLBP+ cells. Im-
munofluorescence analysis of CD133 confirmed
expression in positively (A) but not negatively (B)
sorted cells. FISH analysis using probes against
1p (green) and 1q (red) confirmed that CD133+
(C) and CD133− (D) cell fractions display gain
of 1q and are therefore cancer cells. Immuno-
fluorescence analysis of acutely sorted ependy-
moma cells also confirmed that CD133+ cells
(red) coexpress BLBP (green) (E) and RC2
(green) (F). In contrast, CD133 (red)-positive
medulloblastoma cells do not express BLBP
(green) (G). H: Tumor (T, outlined) in the lateral
ventricle (LV) of a mouse resulting in marked
ventricular dilatation. I: Hematoxylin and eosin
stain of the tumor demonstrating the typical ap-
pearance of an ependymoma (×400). Immuno-
histochemical analysis of GFAP (J) and β-III-
tubulin (K) by an engrafted ependymoma. L:
Immunofluorescence analysis of BLBP expression
(red) by the same ependymoma xenograft. Im-
munohistochemical analysis of Aquaporin 1 (M,
arrows indicate immunopositive cells), Aqua-
porin 4 (N), Jagged1 (O), and Hoxa9 (P) by a
xenograft that grew in the lateral ventricle of a
mouse and was formed from CD133+/RC2+/
BLBP+ stem cells isolated from a posterior fossa
tumor. Parallel analysis of Aquaporin 1 (Q),
Aquaporin 4 (R), Jagged1 (S), and Hoxa9 (T)
within the parent posterior fossa tumor con-
firmed that the xenograft recapitulated the
gene expression signature of posterior fossa
ependymoma.expression in ependymoma and are therefore likely to play a
role in the etiology of the disease.
Discussion
Are ependymoma cancer stem cells transformed RGCs?
Here, we present several lines of evidence that suggest that
histologically similar ependymomas from different parts of the
CNS represent molecularly and clinically distinct disease sub-
groups because they arise from different populations of RGCs.
Ependymomas occur most commonly in the wall of the cere-
bral ventricles or in the spinal canal and they display character-
istic ultrastructural and immunohistochemical features of normal
ependymal cells (Kleihues et al., 2002; Liberski, 1996). There-
fore, these tumors are most likely to arise from cells of the
ependymal lineage. Neuroepithelial cells and RGCs, precursors
of ependymal cells, are mitotically active (Kriegstein and Gotz,
2003). Thus, both of these cell types could acquire the mini-
mum number of mutations required for malignant transforma-
tion. Our data suggest that RGCs, rather than neuroepithelial
cells, are stem cells of ependymoma. We show that more than
80% of genes that are expressed at high levels in supratentor-
ial and spinal ependymomas are also present in RGCs in the
corresponding region of the embryonic CNS. Furthermore, self-
renewing and multipotent cancer cells isolated from ependy-
momas exhibit the RGC immunophenotype CD133+/Nestin+/
RC2+/BLBP+, and they reproduce this disease when trans-
planted into mice. Currently, we are conducting serial transplanta-CANCER CELL : OCTOBER 2005tion experiments to confirm that these cells also self-renew in
vivo. Although unlikely, we acknowledge that ependymoma
cancer stem cells could arise from postmitotic ependymal cells
that have reacquired the capacity to self-renew (Capela and
Temple, 2002; Laywell et al., 2000; Spassky et al., 2005). Proof
of principle that self-renewal can be reestablished has been
provided by experiments in which the transduction of hemato-
logic cells with MOZ-TIF2 restored self-renewal and promoted
leukemogenesis (Huntly et al., 2004). In the future, it may be
possible to identify precisely which cells in the ependymal lin-
eage are the primary targets of transformation, by using cell-
specific promoters to drive oncogene expression in different
ependymal precursor populations of transgenic mice.
Which cell signal pathways promote the stem
cell phenotype in ependymoma?
An important question raised by our data is whether the gene
expression profiles that are hallmarks of the respective RGC
populations persist in ependymomas as molecular baggage or
whether they play a functional role in maintaining the cancer
cell phenotype. Notably, the NOTCH cell signal pathway and
HOX family of transcription factors, which we identified as
upregulated in supratentorial and spinal ependymomas, re-
spectively, regulate stem cell self-renewal (Huntly and Gilliland,
2005; Pardal et al., 2003). For example, aberrant Notch signal-
ing expands the neural stem cell fraction in the developing
mouse and inhibits neurogenesis (Hitoshi et al., 2002). Simi-
larly, exposure of hematologic cell populations to JAGGED1331
A R T I C L EFigure 7. Ependymomas from different parts of the CNS display distinct patterns of copy number-driven gene expression
Solid black circles represent individual DNA regions that were identified as significantly altered in supratentorial (n = 4), spinal (n = 3), posterior fossa group
2 (n = 6), and posterior fossa group 3 (n = 4) ependymomas, by aCGH analysis. The genomic location of each region is shown on the graph. The vertical
position of each circle represents the relative average gain (>1 mean aCGH ratio) or deletion (<1 mean aCGH ratio) of each region among tumors in the
corresponding disease subgroup. Squares report the relative average expression of genes mapping within the corresponding altered genomic region (see
Table S4 for a full list of genes). Squares falling above each circle represent genes that are relatively overexpressed in tumors containing the corresponding
genomic alteration: genes that are relatively underexpressed are shown below each circle. The distance of each square from the circle represents the
degree to which the gene is under- or overexpressed. Genes that are significantly over- or underexpressed in tumors containing the corresponding DNA
alteration are shown in red. Genes displaying nonsignificant expression changes are shown in blue. The size of each square reports the degree of statistical
significance of the expression difference.increases the proportion of stem cells while reducing the num-
bers of differentiating cells (Varnum-Finney et al., 1998). Inter-
estingly, aberrant NOTCH signaling appears to specifically
transform only cells in which the G0/G1 checkpoint is dis-
rupted (Radtke and Raj, 2003). Thus, the markedly elevated
levels of JAGGED1 observed in supratentorial ependymomas
could contribute to the self-renewal capacity of ependymoma
stem cells in the cerebral SVZ. Further, this might be facilitated
by deletion of INK4A/ARF, which we observed as a frequent
event in supratentorial ependymomas. Similarly, aberrant ex-
pression of HOXA9 may maintain the cancer stem cell pheno-
type in spinal ependymomas, since increased expression of
this transcription factor has been shown to transform hemato-
logic stem cells and promote leukemogenesis (Huntly and Gilli-
land, 2005).
Implications for the clinic
Our data complement and extend previous studies of medul-
loblastoma and glioma indicating that brain tumors are propa-
gated by small fractions of tumorigenic stem cells (Singh et al.,
2004a). If proved correct, then these findings would lead to a
paradigm shift in the way we treat CNS tumors. Rather than
employing nonspecific therapies guided by crude measures of332disease type, to treat the primary tumor mass, we should de-
velop classification systems and targeted treatment strategies
focusing on the eradication of cancer stem cells (Pardal et al.,
2003). This strategy may prove particularly effective in tumors,
such as ependymoma, that are comprised of developmentally
and molecularly distinct subgroups that are unlikely to respond
uniformly to all treatments.
One of the most immediate clinical applications of cancer
stem cell biology is the generation of prognostic tools (Glinsky
et al., 2005; Singh et al., 2003). However, there is a greater need
for better treatments of ependymoma, since the survival of pa-
tients with partially resected ependymoma is extremely poor
(Bouffet et al., 1998). At least two aspects of the biology of
cancer stem cells could be exploited as new therapeutic tar-
gets. Stem cells are distinguished from their differentiated
progeny by the expression of high levels of ATP binding cas-
sette (ABC) transporters (Dean et al., 2005). These proteins are
not required for stem cell growth or maintenance, but they
likely serve a protective function that prevents stem cells from
accumulating toxins (Schinkel et al., 1994; Zhou et al., 2002).
Unfortunately, ABC transporters are also highly effective at ex-
cluding drugs from cells, and this may explain why normal and
malignant stem cells are peculiarly resistant to certain chemo-CANCER CELL : OCTOBER 2005
A R T I C L Etherapeutics (Dean et al., 2005). Interestingly, supratentorial
ependymomas expressed significantly higher amounts of the
ABC transporter ABCG1 relative to ependymomas elsewhere
in the CNS (2.5-fold increase in expression; p < 0.0005; see
Table S1). Thus, inhibitors of ABC transporters may prove to be
useful therapeutics to increase the sensitivity of ependymoma
cancer stem cells to conventional treatments (Dean et al., 2005).
Targeting the pathways that regulate aberrant self-renewal
represents an alternative approach to attacking stem cells in
cancer (Pardal et al., 2003). The success of this approach will
depend on our ability to develop drugs that selectively target
cancer stem cells while sparing their normal counterparts. This
issue is especially important when treating brain tumors in chil-
dren, whose nervous systems are still developing. The extent
to which normal neural stem cells repair radiation-induced
damage in the brain is not known. Thus, relatively nonselective
drugs that target both normal and malignant stem cell fractions
might compound the deleterious effects of radiation therapy.
These issues aside, there is a real possibility that drugs that
inhibit the self-renewal of cancer stem cells could offer new
hope to patients with refractory malignancies such as ependy-
moma. Indeed, one class of drugs, inhibitors of γ-secretase,
are being considered for clinical trials in leukemia and could
have utility in the treatment of supratentorial ependymoma
(Huntly and Gilliland, 2005). Binding of JAGGED ligands to
NOTCH leads to γ-secretase-mediated cleavage of the NOTCH
receptor and activation of signaling (Radtke and Raj, 2003).
Thus, if JAGGED1 contributes to the stem cell phenotype in
supratentorial tumors, then inhibitors of γ-secretase might be
effective against these tumors.
The approach used here to identify ependymoma cancer
stem cells and the corresponding normal progenitor cells could
be readily adapted to the analysis of other organ systems.
While cancer stem cells have been isolated from solid tumors
of the brain and breast, the relationship of these cells to normal
progenitors in the respective tissues of origin is unknown (Al-Hajj
and Clarke, 2004; Singh et al., 2004a). We demonstrate that
screening developing tissues for cells that exhibit the signature
gene expression profiles of tumor subsets can identify progeni-
tor cells that may represent the cellular targets of primary mu-
tations that promote disease. Thus, molecular archeology
studies of tumor stem cells could reveal the susceptible pro-
genitor cell population that gives rise to many distinct cancer
subtypes.
Experimental procedures
Patient samples
Clinical material was collected under protocol XPD01-092 (St. Jude Chil-
dren’s Research Hospital Institutional Review Board) and subject to central
histopathology review. Tumor samples were snap frozen at the time of surgi-
cal resection or immediately disaggregated into single-cell suspensions and
cultured as described below. A separate, nonoverlapping cohort of forma-
lin-fixed, wax-embedded ependymoma samples were also collected and
incorporated into a TMA. RNA and DNA were extracted from fresh-frozen
tumor samples using Trizol as directed by the manufacturer and were stored
at −80°C until use.
Oligonucleotide RNA expression array analysis
Gene expression profiles were generated using total RNA and the U133Av2
array (Affymetrix) that analyzes the expression level of 18,400 transcripts
and variants, including 14,500 well-characterized human genes (Hernan et
al., 2003). Gene expression data were normalized using the MAS5 algorithmCANCER CELL : OCTOBER 2005and then transformed by taking the logarithm (base 2) and the coefficient
of variation (CV) calculated for each probe set across all samples. The top
1000 most variable probe sets were selected for unsupervised hierarchical
clustering based on Z scores using Pearson correlation as the similarity
metric.
We used analysis of variance (ANOVA) to identify probe sets that discrimi-
nated tumor subtypes. To correct for the multiple hypothesis testing prob-
lem, false discovery rates (q values) were calculated from the ANOVA p
values (Storey and Tibshirani, 2003). Probe sets with q values less than 0.05
were then filtered further to remove probe sets with intergroup fold changes
of less than 1.5. Selected probe sets were then used for supervised hierar-
chical clustering.
aCGH
Total genomic DNA from test samples and sex-matched reference DNA
samples were processed and analyzed using BAC array CGH exactly as
described previously (Loo et al., 2004). For a full description of this array,
the reader is referred to Loo et al. (2004). Briefly, this array includes 4171
different BAC clones with a median spacing of 413 kb when pericentric
heterochromatic regions and the short arms of acrocentric chromosomes
are excluded (25th percentile, 160 kb; 75th percentile, 878 kb; mean, 677
kb). The locations of 4153 clones have been verified by FISH.
We performed a global within-slide normalization to remove intensity-
dependent bias using the robust scatter plot smoother “loess” and then
performed a multiple slide scale normalization to facilitate between-slide
comparisons using the median absolute deviation (MAD) with Bioconductor
version 1.5. An average ratio was then calculated for each BAC clone, since
each BAC clone was spotted twice per microarray.
Thresholds reporting chromosome gains or losses for each BAC were
calculated using the extreme studentized deviate (ESD) statistic:
ESD = maximum of Zi=1,…,n = |Xi− X¯| /S
where X1, . . ., Xn denote the ratios across samples, and X¯ and S denote
the mean and standard deviation for sample ratios for a specific BAC clone.
This approach assumes that ratios from samples without DNA copy number
changes follow a Gaussian distribution for a specific BAC clone and that
ratios from samples with DNA copy number changes are outliers relative to
Gaussian distribution for same BAC clone. We then used an established
ESD-based procedure to detect outliers. BAC clones that had either gain
or loss at more than or equal to three samples were then selected for unsu-
pervised hierarchical clustering using Euclidean distance as a similarity
metric.
To evaluate the influence of DNA copy number changes on gene expres-
sion, we identified all Affymetrix probe sets that mapped within significantly
varying BAC aCGH clones. aCGH data were represented by a vector that
was labeled 1 for a sample with DNA copy number change and 0 for no
change. DNA copy number changes were then correlated with gene expres-
sion using the t-like statistic defined as the difference of the means of the
gene expression values in the altered and unaltered sample groups divided
by the sum of the standard deviations of the expression values in altered
and unaltered sample groups. To assess the significance of each statistic
for each gene, we performed random permutations of the label vector of
samples. The probability that a gene has a larger or equal statistic by ran-
dom permutation than the original statistic is denoted by α. A low α (<0.05)
indicates a strong association between gene expression and DNA copy
number changes.
In situ hybridization analysis
Cryosections (16 m) were prepared from 4% paraformaldehyde (PFA)-
fixed whole brains and spinal cord taken from E11.5, E15.5, and postnatal
day 7 (P7) C57BL/6 mice. 33P-UTP riboprobes were generated by in vitro
transcription. Following incubation with 1 × 106 cpm of probe, slides were
rinsed through a series of posthybridization washes, air-dried, and exposed
to emulsion.
Cell culture and orthotopic transplants
Immediately following surgical resection, tumors were minced and digested
with collagenase type IV and hyaluronidase for 60 min at 37°C. Cells were
then grown on Matrigel (BD BioSciences)-coated dishes in Neurobasal me-
dium (Invitrogen) containing 2 mM L-glutamine, N2 supplement (Invitrogen),333
A R T I C L EB27 supplement (Invitrogen), 20 ng/ml hrEGF (Invitrogen), 20 ng/ml hrbFGF
(Invitrogen) and 50 g/ml BSA in 5% CO2. Serial dilutions of single-cell
suspensions were made in 96 well plates. The number of tumor spheres/
well was quantified after 7 days. For differentiation studies, tumor spheres
were transferred to culture slides coated with poly-L-ornithine and laminin
and incubated in Neurobasal medium without growth factors for 72 hr. All
cell cultures were subject to spectral karyotype analysis to confirm the pres-
ence of malignant clones.
Human ependymoma cells were sorted using antibody coated magnetic
beads (100l/108 cells, Miltenyi Biotec). Sorted cells were resuspended in
Matrigel (5 l; BD BioScience) and implanted intracranially into 7- to 8-week-
old NOD/SCID mice at a depth of 3.5 mm. Purity of the sorted cell popula-
tions was confirmed by immunocytochemistry using anti-CD133/2 (Mil-
tenyi Biotec).
FISH and immunohistochemical analyses
Dual-color FISH and immunohistochemical analyses of formalin-fixed paraf-
fin-embedded tumor samples or tumor cell spheres were performed using
routine methods. Full details of all immunoreagents used in this study are
provided in Table S5. All FISH probes were validated on normal control
metaphase spreads to verify chromosomal localization.
Supplemental data
The Supplemental Data include five supplemental tables and can be found
with this article online at http://www.cancercell.org/cgi/content/full/8/4/
323/DC1/.
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